Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

YARS2 Antikörper (C-Term)

YARS2 Reaktivität: Human WB, IHC (p) Wirt: Kaninchen Polyclonal RB14936 unconjugated
Produktnummer ABIN1882153
  • Target Alle YARS2 Antikörper anzeigen
    YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))
    Bindungsspezifität
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 399-427, C-Term
    Reaktivität
    • 22
    • 11
    • 5
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    Human
    Wirt
    • 21
    • 1
    Kaninchen
    Klonalität
    • 22
    Polyklonal
    Konjugat
    • 15
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser YARS2 Antikörper ist unkonjugiert
    Applikation
    • 14
    • 5
    • 4
    • 4
    • 3
    • 2
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Homologie
    M, Rat
    Aufreinigung
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This YARS2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 399-427 amino acids from the C-terminal region of human YARS2.
    Klon
    RB14936
    Isotyp
    Ig Fraction
    Top Product
    Discover our top product YARS2 Primärantikörper
  • Applikationshinweise
    WB: 1:1000. IHC-P: 1:10~50
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Haltbarkeit
    6 months
  • Riley, Menezes, Rudinger-Thirion, Duff, de Lonlay, Rotig, Tchan, Davis, Cooper, Christodoulou: "Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia." in: Orphanet journal of rare diseases, Vol. 8, pp. 193, (2014) (PubMed).

    Riley, Cooper, Hickey, Rudinger-Thirion, McKenzie, Compton, Lim, Thorburn, Ryan, Giegé, Bahlo, Christodoulou: "Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome." in: American journal of human genetics, Vol. 87, Issue 1, pp. 52-9, (2010) (PubMed).

    Bonnefond, Frugier, Touzé, Lorber, Florentz, Giegé, Sauter, Rudinger-Thirion: "Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features." in: Structure (London, England : 1993), Vol. 15, Issue 11, pp. 1505-16, (2007) (PubMed).

  • Target
    YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))
    Andere Bezeichnung
    YARS2 (YARS2 Produkte)
    Synonyme
    2210023C10Rik antikoerper, tyrRS antikoerper, CGI-04 antikoerper, RGD1311696 antikoerper, MLASA2 antikoerper, MT-TYRRS antikoerper, TYRRS antikoerper, tyrosyl-tRNA synthetase 2 (mitochondrial) antikoerper, tyrosyl-tRNA synthetase 2 antikoerper, Yars2 antikoerper, YARS2 antikoerper
    Hintergrund
    YARS2 catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
    Molekulargewicht
    53199
    NCBI Accession
    NP_001035526
    UniProt
    Q9Y2Z4
Sie sind hier:
Kundenservice